Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 0 · 0%High 0 · 0%

Anticoagulant vs different dose of the same anticoagulant

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with different dose of the same anticoagulant (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.47 [0.09, 2.54]
1 study · 278 participants
Low

Anticoagulant vs antiplatelet agent

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with antiplatelet agent (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 2.13 [0.4, 11.46]
1 study · 279 participants
Low

Anticoagulant vs placebo or no treatment

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 2.46 [0.9, 6.72]
5 studies · 1777 participants
Low

Anticoagulant with or without ASA vs ASA only

Minor bleeding · people with antiphospholipid antibodies and no history of thrombosis

Anticoagulant with or without ASA may leads to higher bleeding ‐ minor (not requiring hospital admission) Median compared with ASA only (low certainty).

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
RR 22.45 [1.34, 374.81]
1 study · 164 participants
Low

Anticoagulants (chosen at investigators' discretion) vs placebo

Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found